Bayer’s cooperation partner, Janssen Research & Development, L.L.C. has submitted a Supplemental New Drug Application ( sNDA ) to the U.S. Food and Drug Administration (FDA) for the oral anticoagulant Xarelto ( rivaroxaban ) in combination with standard antiplatelet therapy to reduce the risk of (thrombotic) cardiovascular events in patients with Acute Coronary Syndrome (ACS).

Nearly 26 million Americans have diabetes, and another 79 million have prediabetes. That's about 30 percent of all Americans with a diabetes problem.